HCV has been associated with the development of B-cell non-Hodgkin's lymphomas. We recently reported the regression of splenic lymphoma with villous lymphocytes (SLVL) in HCV patients after antiviral treatment, demonstrating a direct role of HCV in lymphomagenesis. This study expands our previous results in 18 patients with chronic HCV and SLVL. Mixed cryoglobulinemia (MC) was present in all cases and was symptomatic in 13 (72%). All patients were treated with IFN alone or in association with ribavirin.
INTRODUCTION
Hepatitis C virus (HCV) is associated with a spectrum of extrahepatic manifestations, mainly mixed cryoglobulinemia (MC). MC-producing B-cells are mostly monoclonal and a significant proportion of MC can evolve into overt B-cell lymphoma. As such, HCV-MC is considered as a low-grade B-cell lymphoproliferative disorder. A link between HCV infection and B-cell non Hodgkin's lymphoma (NHL) has been suggested by many epidemiological studies [1] [2] [3] . In a meta-analysis, the prevalence of HCV infection in patients with B-cell NHL was 15% compared to 1,5% in the general population 4 . Although most histological subtypes of B-cell lymphomas have been described in association with HCV 5 , lymphoplasmocytic lymphomas, marginal zone lymphomas (MZL) and large B-cell lymphomas are more common in HCV infected individuals 3, 6, 7 . These epidemiological studies establish the association between HCV infection and B-cell NHL but shed no light on the pathogenic role of the virus in the development of lymphomas.
Splenic lymphoma with villous lymphocytes (SLVL) is a chronic B-cell lymphoproliferative disorder characterized by a clonal expansion of atypical B lymphocytes with villous projections in peripheral blood. SLVL involves mainly the spleen and the bone marrow.
Villous lymphocytes have immunological and phenotypical characters of marginal zone lymphocytes. SLVL is usually treated by splenectomy and/or chemotherapy, with an overall 5-years survival of 80% 8 .
We recently reported the regression of SLVL in HCV patients after antiviral treatment 9 , demonstrating a direct role of HCV in lymphomagenesis. The present study expands our previous results in a cohort of 18 patients with chronic HCV and SLVL.
STUDY DESIGN
Between 1993 and 2003, 18 patients from several French centers with SLVL and HCV infection were treated with antiviral therapy. Clinical, biological data and outcome were
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From analyzed. The diagnosis of SLVL was based on the presence of typical clinical, hematological, and immunological findings as previously described 8, 10 . All blood smears and immunophenotype findings were reviewed by two expert cytologist (FV, XT). MC-positive patients were defined as having a MC in their serum > 0.05 g/L, on at least two determinations. Symptomatic MC was defined by serum MC associated with the triad of purpura-arthralgia-asthenia and sometimes with renal or neurologic involvement 11 .
Patients received 3 millions international units recombinant IFN -2b, subcutaneously three times a week for 6 months. In case of a partial response (>50%), treatment was continued until a complete clinical response was achieved. In SLVL/HCV+ patients, diagnosed after 1996, ribavirin (1000 to 1200 mg/d) was added to IFN treatment.
Complete response was defined as disappearance of HCV-RNA, the resolution of splenomegaly, a platelet count greater than 100 x 10 9 /L, an absolute neutrophil count > 1 x 10 9 /L, an hemoglobin level greater than 10 g/dl, and the absence of circulating blood villous lymphocytes. Partial response was defined by a palpable but reduced spleen size by at least 50%, associated with an improvement of the blood hematological parameters over baseline (>50%) and detectable HCV-RNA. Treatment failure and disease progression were defined as a persistent or progressive increase in the number of peripheral blood villous lymphocytes and/or splemomegaly, respectively. Relapse was defined as a progressive increase in the number of peripheral blood villous lymphocytes and/or increasing splenomegaly after an initial complete or partial response.
RESULTS AND DISCUSSION
All 18 patients had type II mixed cryoglobulinemia with MC-vasculitis symptoms in 13 (72%) ( Table 1) , a much higher frequency than usually noted in cryoglobulin-positive HCV patients 12 . Clinical symptoms of MC preceded the diagnosis of SLVL in 7 patients (mean of 3.5 years before SLVL diagnosis) and were contemporaneous in the other 6 patients. Except
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SLVL may be integrated in the spectrum of cryoglobulin associated B-cell proliferations.
HCV genotype 1 was observed in 7 of our patients. Despite of the usual resistance of this genotype to antiviral therapy, 4 of these patients achieved a complete hematological response after INF and ribavirin.
Four patients had received a first line therapy for SLVL (splenectomy (n=2), chemotherapy (n=2) or both (n=1)) prior to antiviral therapy. Of the 18 patients treated with interferon ( Complete hematologic and virologic response was seen in 14 of 18 patients (78%). Mean time to hematologic response (decrease in lymphocyte counts) was 2.8 ± 2.7 months (range, 1-11).
There was a correlation between virological and hematological status as all patients who cleared HCV had a sustained hematological response after a mean follow-up of 62.3 months.
In one patient, relapse of SLVL coincided with reappearance of serum HCV RNA.
Reinitiation of antiviral therapy led to a second complete response. Two patients who had a partial virological response (>2 logs reduction in HCV RNA) achieved a complete hematological respone whereas the two patients who exhibited a lower reduction of HCV RNA levels had only a partial hematological response. Clinical manifestations of MC subsided in all patients with a complete virological response. In all 14 patients in whom molecular studies were performed, the monoclonal immunoglobulin gene rearrangement was still detectable in the blood even though a complete hematological response was achieved. These findings contrast with previous reports stating the disappearance of B-cell clones in the blood of HCV infected patients after antiviral therapy [14] [15] [16] . This discrepancy may reflect differences in tumor load or in survival requirements. In the case of SLVL, some clones, while remaining antigen-dependant for their proliferation, may survive in the favorable environment of the spleen or bone marrow, even after effective clearance of HCV.
Our findings emphasize that antiviral therapy should be the first choice of treatment of HCV patients with SLVL. Severe symptomatic MC, may initially require treatment with steroids, immunosuppressive drugs or plasma exchange 17 . In most cases, however, antiviral therapy led to the rapid disappearance of symptoms even when cryoglobulinemia and lymphoma were still detectable. Recently, Levine et al reported effective therapy against HCV in a case of HCV-associated mantle-cell lymphoma 18 . Antiviral therapy may also induce complete remission of lymphoplasmatic lymphoma or immunocytoma 16 and marginal-zone lymphoproliferation 13, 19, 20 .
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